Trials / Unknown
UnknownNCT00491296
Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- HaEmek Medical Center, Israel · Academic / Other
- Sex
- Male
- Age
- 30 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control. Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | SYNERGO | |
| DEVICE | SYNERGO-intravesical chemotherapy instillation combined with hyperthermia |
Timeline
- Start date
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2007-06-26
- Last updated
- 2008-11-07
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT00491296. Inclusion in this directory is not an endorsement.